Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05698511
Other study ID # 21-35696
Secondary ID 157762
Status Recruiting
Phase Phase 1
First received
Last updated
Start date July 31, 2023
Est. completion date November 30, 2025

Study information

Verified date August 2023
Source University of California, San Francisco
Contact Robin Carhart-Harris, PhD
Phone (415) 476-1000
Email insight2@ucsf.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this study is to gain a better understanding of the distinct mental states and physical reactions that can arise during a psychedelic experience. By repeatedly assessing the same participants in an MRI while under the effects of psilocybin, the investigators want to identify reliable brain and body reactions arising during these psychedelic experiences. It is hoped that this will provide an insight to inspire future research on psilocybin and related psychedelics as well as inform on their therapeutic action. This study will involve up to 12 healthy volunteers with previous psychedelic experience. Participants in this study will be given four doses of psilocybin, with breaks of at least seven days in between dosing visits. The first dosing visit will feature a 10 mg dose of psilocybin, which can be considerate a low to moderate dose, whereas the remaining three dosing visits will feature 25 mg psilocybin, a high dose that is consistent with the dosage chosen for several modern clinical trials with psilocybin. From the initial in-person screening visit to the final follow-up, participants will be in this study for approximately 6-12 weeks and visit the research site 5 times. The first visit will be an in-person screening visit, during which the investigators will assess participants' eligibility to be enrolled. There will be 4 subsequent visits to the scan center for dosing and magnetic resonance imaging (MRI) scanning, and there will be a final remote follow up. Each of the four dosing visits will include four periods of lying within the MRI scanner for scanning, each of these 'in-scanner' sessions will last for ~ 45 minutes. Actual scans, which are also called 'runs' last for ~ 12 mins. During these 'runs', the investigators will ask participants two brief questions about how positive or negative their current experience is every 100 seconds. They will be able to record their answers using a button box which they will be operating with their hand. One day after each dosing visit, the investigators will schedule a phone call with the participant to check how they are doing and perform an informal interview focused on their experience while under the effects of psilocybin.


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date November 30, 2025
Est. primary completion date November 30, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 70 Years
Eligibility Inclusion Criteria: 1. Have at least one previous experience with a psychedelic substance 2. Have no more than 500 previous experiences with a psychedelic substance. It will be an advantage to recruit persons to this study with ample prior experience with psychedelics and no history of responding adversely; however, an excessive history of use might signify abuse of these compounds. 3. Have no history of a severe negative response to a psychedelic e.g., severe, and enduring anxiety, depression, or psychotic symptoms 4. Are between 21 and 70 years of age 5. Are fluent in speaking and reading English 6. Can swallow pills/capsules 7. If able to become pregnant, must be non-lactating, have a negative pregnancy test at study entry and prior to each Experimental Session and must agree to an adequate form of birth control and contraception over the course of the study. Adequate forms of birth control or contraception include intrauterine device (IUD), injected, implanted, intravaginal, or transdermal hormonal methods, abstinence, oral hormones plus a barrier contraception, vasectomized sole partner, or double barrier contraception. Two forms of contraception are required with any barrier method or oral hormones (i.e. condom plus diaphragm, condom or diaphragm plus spermicide, oral hormonal contraceptives plus spermicide or condom). Not of childbearing potential is defined as documented hysterectomy, bilateral salpingectomy, bilateral oophorectomy, and/or tubal ligation), permanently sterile by medical device such as Essure, postmenopausal, or male by birth. Contraception applies to males as well as females and male participants must not be planning sperm donation within the study period. 8. Able and willing to provide informed consent 9. Able and willing to use computers and tablets or phones to enter electronic data 10. Agree to inform the investigators within 48 hours of any new or changed medical conditions. Exclusion Criteria: 1. Have no previous experience a psychedelic substance 2. Have a current diagnosed psychiatric disorder that, in the opinion of the study clinician interferes with activities of daily living, could impact attendance at or participation in study activities, or requires a more therapeutically structured context for psilocybin than can be provided within the constraints of this study's design. 3. Have a current or previously diagnosed psychotic disorder 4. Have a current or previously diagnosed psychiatric disorder that renders them unsuitable for the study (e.g., borderline personality disorder) 5. Have one or more immediate family members (i.e., parent or sibling) with a current or previously diagnosed psychotic disorder, e.g., schizophrenia. 6. Have a medically significant condition that renders them unsuitable for the study (e.g., cardiovascular or cerebrovascular conditions for which an acute increase in blood pressure (BP) would be clinically concerning, hepatic or renal disease, etc.). 7. Systolic and diastolic BP values of >155 SBP and >95 DBP would result in exclusion from the study. 8. Present with a QTc > 450 msec or with evidence of cardiac damage, ischemia, or heart disease. 9. Have a recent history of suicidal ideation or attempted suicide that, in the opinion of the study clinician or PI, may present a risk of suicidal or self-injurious behavior 10. Have MRI contraindications (e.g., metal implants, pacemakers, claustrophobia etc.) as determined by an MRI contraindications questionnaire 11. Have used alcohol within 24 hours or other psychoactive drugs within 7 days of an Experimental Session (with the exception of the psilocybin used within this study). NB the study researchers and PI may decide to continue with procedures if a positive drug-screen result is seen for cannabis use, or the participant openly declares recent cannabis-use; however, we might consider factoring in cannabis use in subsequent analyses and would strongly discourage any further use and consider exclusion if not reassured that the participant will comply with this request. 12. Current chronic cannabis use 13. Give a positive alcohol breathalyzer test result on any study visit 14. Are currently taking any of the medications or substances listed in Appendix 1 or, in the opinion of the study clinician or PI, engage in excessive use of alcohol or recreational drugs, particularly cannabis, which is legally available in California 15. Are breastfeeding, or have a positive pregnancy test at screening or at any point during the course of the study 16. Have an allergy or intolerance to any of the materials contained in the drug product 17. Have any current problem which, in the opinion of the investigator or clinician, might interfere with participation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Psilocybin
Multiple dosing of healthy volunteers with up to 25 mg psilocybin separated from each other by at least one week. Participants will be scanned before and after receiving psilocybin on each dosing day. Surveys will be performed on dosing days and after dosing.

Locations

Country Name City State
United States University of California, San Francisco San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
Robin Carhart-Harris, PhD, MA

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The WHO - Five Well-Being Index (WHO-5) Measure of psychological well-being Baseline (visit 0) vs 4 weeks post visit 4
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1